Los Angeles Capital Management LLC Raises Holdings in Rhythm Pharmaceuticals, Inc. $RYTM

Los Angeles Capital Management LLC boosted its holdings in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) by 45.5% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 24,334 shares of the company’s stock after acquiring an additional 7,613 shares during the quarter. Los Angeles Capital Management LLC’s holdings in Rhythm Pharmaceuticals were worth $2,721,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of RYTM. EverSource Wealth Advisors LLC increased its holdings in Rhythm Pharmaceuticals by 303.0% during the fourth quarter. EverSource Wealth Advisors LLC now owns 266 shares of the company’s stock valued at $28,000 after buying an additional 200 shares during the period. Smartleaf Asset Management LLC increased its holdings in Rhythm Pharmaceuticals by 97.2% during the third quarter. Smartleaf Asset Management LLC now owns 286 shares of the company’s stock valued at $29,000 after buying an additional 141 shares during the period. Optiver Holding B.V. increased its holdings in Rhythm Pharmaceuticals by 65.2% during the third quarter. Optiver Holding B.V. now owns 365 shares of the company’s stock valued at $37,000 after buying an additional 144 shares during the period. SBI Securities Co. Ltd. increased its holdings in Rhythm Pharmaceuticals by 73.2% during the fourth quarter. SBI Securities Co. Ltd. now owns 343 shares of the company’s stock valued at $37,000 after buying an additional 145 shares during the period. Finally, GAMMA Investing LLC increased its holdings in Rhythm Pharmaceuticals by 48.6% during the fourth quarter. GAMMA Investing LLC now owns 361 shares of the company’s stock valued at $39,000 after buying an additional 118 shares during the period.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on RYTM shares. Wall Street Zen raised shares of Rhythm Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, May 9th. Morgan Stanley cut their price objective on shares of Rhythm Pharmaceuticals from $150.00 to $136.00 and set an “overweight” rating on the stock in a report on Tuesday, March 17th. Citigroup reissued a “market outperform” rating on shares of Rhythm Pharmaceuticals in a report on Wednesday, June 3rd. Royal Bank Of Canada lifted their price objective on shares of Rhythm Pharmaceuticals from $136.00 to $137.00 and gave the company an “outperform” rating in a report on Wednesday, May 6th. Finally, Zacks Research raised shares of Rhythm Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Tuesday, February 17th. One research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $131.81.

Rhythm Pharmaceuticals Stock Up 2.2%

Shares of RYTM opened at $87.86 on Wednesday. The company has a market cap of $6.02 billion, a price-to-earnings ratio of -28.07 and a beta of 1.91. Rhythm Pharmaceuticals, Inc. has a twelve month low of $60.70 and a twelve month high of $122.20. The company has a 50 day moving average of $87.77 and a two-hundred day moving average of $96.59.

Rhythm Pharmaceuticals (NASDAQ:RYTM) last announced its earnings results on Tuesday, May 5th. The company reported ($0.83) earnings per share for the quarter, beating the consensus estimate of ($0.86) by $0.03. The company had revenue of $60.11 million during the quarter, compared to the consensus estimate of $55.78 million. Rhythm Pharmaceuticals had a negative net margin of 93.33% and a negative return on equity of 203.25%. Rhythm Pharmaceuticals’s revenue was up 83.8% compared to the same quarter last year. During the same period last year, the firm earned ($0.81) earnings per share. On average, sell-side analysts expect that Rhythm Pharmaceuticals, Inc. will post -3.07 EPS for the current year.

Rhythm Pharmaceuticals Company Profile

Rhythm Pharmaceuticals, Inc is a clinical‐stage biotechnology company dedicated to developing targeted therapies for rare genetic diseases of obesity and metabolic dysfunction. The company’s research focuses on the melanocortin‐4 receptor (MC4R) pathway, which plays a central role in regulating appetite, energy expenditure and body weight. Using proprietary peptide technology, Rhythm aims to provide precision treatments to patients with specific genetic variants that disrupt normal weight regulation.

The company’s lead investigational product, setmelanotide, is a selective MC4R agonist designed to restore signaling in patients with deficiencies in genes such as POMC, LEPR and PCSK1.